Lymphoma Clinical Trials in Detroit

Showing 161-180 of 297 trials

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT00750009

RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial. It is not known whether providing personalized information is more effective than basic information in helping patients make decisions about clinical trials. PURPOSE: This randomized phase III trial is studying personalized information to see how well it works compared with basic information in helping patients make decisions about participating in a clinical trial.

Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+6 more

Case Comprehensive Cancer Center583 participantsStarted Apr 2008

Detroit, Michigan, United States • Cleveland, Ohio, United States • Cleveland, Ohio, United States +1 more locations

COMPLETEDPHASE212 miles

A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

NCT00042666

This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).

Non-Hodgkin's Lymphoma

Eli Lilly and Company55 participantsStarted Jun 2002

Royal Oak, Michigan, United States • Minneapolis, Minnesota, United States • Rochester, Minnesota, United States

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Lymphoma Trials in Other Cities

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Other Conditions in Detroit